Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3457263 in Type 2 Diabetes Mellitus on Semaglutide or Tirzepatide
NCT06897475Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Modified Peptides, Native Peptides
- Countries
- 6
01
Overview
A Phase 2 trial of nisotirostide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Mar 2025; status: recruiting.
02
Drugs
nisotirostide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06897475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897475.